Pierre Legault Syndax Pharmaceuticals Inc (SNDX) insider trading activity

Pierre Legault is of Syndax Pharmaceuticals Inc. Currently has a direct ownership of 65,000 shares of SNDX, which is worth approximately $849,550. The most recent transaction as insider was on Feb 07, 2024, when has been sold 17,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 65K

0% 3M change

35.42% 12M change

Total Value Held $849,550

Pierre Legault Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 07 2024	BUY Grant, award, or other acquisition	-	17,000 Added 20.73%	65,000 Common Stock
Feb 02 2023	BUY Grant, award, or other acquisition	-	16,000 Added 25.0%	48,000 Common Stock
Jan 13 2023	SELL Open market or private sale	$405,000 $27.0 p/Share	15,000 Reduced 31.91%	32,000 Common Stock
Jan 13 2023	BUY Exercise of conversion of derivative security	$203,700 $13.58 p/Share	15,000 Added 28.85%	37,000 Common Stock
Jan 12 2023	SELL Open market or private sale	$641,760 $26.74 p/Share	24,000 Reduced 42.86%	32,000 Common Stock
Jan 12 2023	BUY Exercise of conversion of derivative security	$227,280 $9.47 p/Share	24,000 Added 30.0%	56,000 Common Stock
Aug 05 2022	SELL Open market or private sale	$552,480 $23.02 p/Share	24,000 Reduced 42.86%	32,000 Common Stock
Aug 05 2022	BUY Exercise of conversion of derivative security	$222,720 $9.28 p/Share	24,000 Added 34.29%	46,000 Common Stock
Feb 02 2022	BUY Grant, award, or other acquisition	-	16,000 Added 33.33%	32,000 Common Stock
Dec 22 2021	SELL Open market or private sale	$528,240 $22.01 p/Share	24,000 Reduced 60.0%	16,000 Common Stock
Dec 22 2021	BUY Exercise of conversion of derivative security	$189,120 $7.88 p/Share	24,000 Added 37.5%	40,000 Common Stock
Dec 20 2021	SELL Open market or private sale	$420,200 $21.01 p/Share	20,000 Reduced 55.56%	16,000 Common Stock
Dec 20 2021	BUY Exercise of conversion of derivative security	$141,600 $7.08 p/Share	20,000 Added 35.71%	36,000 Common Stock
Feb 03 2021	BUY Grant, award, or other acquisition	-	16,000 Added 50.0%	16,000 Common Stock

Also insider at

BCYC

BICYCLE THERAPEUTICS plc Healthcare

Director

UROV

Urovant Sciences Ltd.

Director

Pierre Legault

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SNDX shares.

Notify only if

Value

Insider Trading

Get notified when an Syndax Pharmaceuticals Inc insider buys or sells SNDX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Syndax Pharmaceuticals Inc

Track Activities on SNDX

Account